Jollibee Group Reports Strong Q1 2025, Fueled by Global Expansion with Strong PH and International Growth
For the quarter ending March 31, 2025, the Jollibee Group reported system-wide sales (SWS) of Php 103.2 billion (US$ 1.76 billion), an increase of 18.9% compared to Php 86.8 billion (US$ 1.48 billion) in the same period last year. Consolidated revenues grew by 14.6% year-over-year to Php 70.2 billion (US$ 1.20 billion). This growth was driven by a combination of 5.5% same store sales growth (SSSG), mainly from volume growth and new store contributions.
Same-Store Sales Growth (SSSG) in the Philippines rose by 8.5%, led by Mang Inasal (+15.9%), Red Ribbon (+11.1%), Jollibee (+8.6%), and Chowking (+6.2%). This drove an 11.9% increase in system-wide sales in Q1 2025, primarily fueled by higher transaction volumes. International SSSG grew slightly by 0.7%, with strong contributions from Europe, Middle East, Asia, and Australia (EMEAA) at +5.3%, North American operations of Asian brands—such as Jollibee, Chowking, and Red Ribbon—at +4.8%, Highlands Coffee +4.4%, Milksha +3.1%, and The Coffee Bean & Tea Leaf (CBTL) +2.8%. The China business declined by 8.3%, although Yonghe King showed sequential improvement in transaction count. Smashburger also posted an 8.0% decline in SSSG, mainly due to lower transaction volumes.
Jollibee Group Global President and CEO Ernesto Tanmantiong commented, 'We are pleased with our first quarter performance, particularly the continued growth in international markets such as Singapore, where our brands are gaining deeper resonance with local and regional consumers. We are proud to see our brands thrive in diverse cultural settings affirming our belief in the global appeal of the Jollibee Group portfolio. We are also optimistic about the addition of another strong brand in our portfolio, Tim Ho Wan, which further strengthens our position in one of the world's most dynamic consumer markets and supports our long-term international growth strategy.'
Jollibee Group's international business saw system-wide sales (SWS) increase by 29.5%. This performance was significantly supported by the acquisition of Compose Coffee, which contributed 17.8% to the international business' SWS growth. The Group's Coffee and Tea segment—now comprising 45.4% of its international SWS—recorded a 62.2% increase, with Compose Coffee accounting for 49% of this growth.
Tim Ho Wan, now 100% owned by the Jollibee Group effective 02 January 2025, contributed to the international business' growth in the quarter.
Flagship brand Jollibee system-wide sales rose by 13.9% globally, with standout performances in several international markets. The Philippines recorded 13.3% growth, China (Hong Kong and Macau) 12.9%, North America 10.9%, Southeast Asia 27.8%, the Middle East 12.9%, Europe 10.9%, and Guam 20.2%.
These results underscore the Jollibee brand's growing global appeal and its positioning to win with consumers across diverse international markets. Singapore alongside other Southeast Asia markets continue to play an important role in the Group's expansion, reflecting increased brand recognition and strong operational performance in the region.
Operating income grew by 17.6% to Php 4.8 billion (US$ 81.9 million), despite a 56.2% increase in advertising and promotions aimed at building brand equity and expanding market reach. The corresponding margin improved by 10 basis points due to higher gross profit levels and a modest rise in general and administrative expenses.
Net income attributable to equity holders of the Parent Company (NIAT) decreased by 8.1% to Php 2.4 billion (US$ 41.0 million), driven by higher below-the-line items. However, quarter-on-quarter, both operating income and NIAT increased by double digits. The year-over-year NIAT decline was largely due to non-operational factors.
Jollibee Group Global Chief Financial and Risk Officer Richard Shin commented, 'We delivered strong revenue and operating income growth while investing meaningfully in brand building. Our disciplined execution and solid operational fundamentals helped us expand margins, even with elevated promotional spending. We remain confident in achieving our full-year 2025 guidance.'
As of March 2025, the Jollibee Group's global store network increased by 44.3% year-over-year to 9,935 stores. This includes 3,393 stores in the Philippines and 6,542 stores internationally, comprising 560 in China, 361 in North America, 393 in EMEAA, 865 with Highlands Coffee primarily in Vietnam, 1,246 with CBTL, 340 with Milksha, 2,700 with Compose Coffee, and 77 with Tim Ho Wan.
The Jollibee Group's performance in Q1 2025 reflects its focused execution and the strength of its global portfolio. The continued success in Southeast Asia, including Singapore, supports its ambition to become one of the top five restaurant companies in the world.
Corporate Action
On the corporate governance front, the Jollibee Group's Board of Directors approved the declaration of a regular cash dividend of Php 1.33 (US$ 0.024) per share of common stock on April 14, 2025. The dividend was released on May 16, 2025, to shareholders of record as of May 2, 2025.
Forward-Looking Statement Disclaimer
The foregoing disclosure contains forward-looking statements that are based on certain assumptions of Management and are subject to risks and opportunities or unforeseen events. Actual results could differ materially from those contemplated in the relevant forward-looking statement, and the Jollibee Group gives no assurance that such forward-looking statements will prove to be correct, or that such intentions will not change. This Press Release discloses important factors that could cause actual results to differ materially from the Jollibee Group's expectations. All subsequent written and oral forward-looking statements attributable to the Jollibee Group or person acting on behalf of the Jollibee Group expressly qualified in their entirety by the above cautionary statements.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
4 hours ago
- New Straits Times
Medicaid, Trump tax cuts 'kick off' 2026 campaign
RESIDENTS of Columbus, Indiana awoke last week to a yellow billboard purchased by the Democratic National Committee (DNC) blaring: "Under Trump's Watch, Columbus Regional Health is Cutting Medical Services." Meanwhile, the National Republican Congressional Committee (NRCC), which oversees races for the United States House of Representatives, last month launched a digital ad campaign touting President Donald Trump's tax cuts and blaming Democrats for spiking inflation. As members of Congress return to their home districts for the August recess, the Democratic and Republican parties are launching ad blitzes centred around the tax-cut and spending bill Trump signed into law on July 4, in an unofficial start to the 2026 midterm election campaign. Democrats are focusing their message around access to healthcare while Republicans are countering that the tax provisions will put more money in voters' pockets. The bill makes permanent Trump's 2017 tax cuts and funds his immigration enforcement crackdown, while reducing healthcare and food aid. It devotes US$170 billion to immigration enforcement while cutting US$1.1 trillion from Medicaid and other public health programmes and US$186 billion in food assistance. The nonpartisan Congressional Budget Office estimated that 10 million people would lose their health insurance by 2034 as a result of the bill, and that the tax provisions and increased immigration and military spending would increase the federal deficit by US$3.4 trillion over the next decade. Republican strategists say they have plenty of time to sell the bill's benefits. "We will use every tool to show voters that the provisions in this bill are widely popular," said Mike Marinella, a spokesman for the NRCC. And the party has a cash advantage. The Republican National Committee (RNC) had US$81 million in cash at the end of June, compared with the DNC's US$15 million during the same period. The RNC also enjoys a huge asset in a sitting president who is still holding fundraisers for big-ticket donors. Republicans can only afford a net loss of two of the 220 seats they hold in the House to maintain control. In the Senate, they have a 53-47 advantage. According to a Reuters/Ipsos poll, conducted last month, some 64 per cent of registered voters oppose cuts to Medicaid and food stamps in return for lower taxes for everyone. Democrats are seizing on that sentiment, pushing the idea that Republicans have taken away healthcare to pay for tax giveaways for billionaires. "Republicans threw working families under the bus to fund tax cuts for the wealthy, and we'll never let them — or voters — forget that," said DNC Deputy Communications Director Abhi Rahman in a statement. "This will define the midterms." Republicans say the bill's provisions on tips, overtime and Social Security show the party is focused on issues affecting working families. They also point to a US$50 billion fund the bill establishes to help rural hospitals. Another Republican strategy memo prepared by Trump's pollsters, urges candidates to "lead on kitchen-table issues." Democrats, meanwhile, are trying to tie Medicaid cuts to reduced healthcare access and higher costs. The DNC's website claims that the bill will "cost the poorest 10 per cent of households US$1,600 a year while raising the income of the richest 10 per cent of Americans by US$12,000 a year". Unrig Our Economy, a left-leaning group, is running ads in Iowa, Arizona and Pennsylvania depicting voters voicing frustration at their Republican lawmakers for voting for Trump's bill. "I'm so angry that Congresswoman Mariannette Miller-Meeks just voted for the largest cut to Medicaid in history to give tax breaks to billionaires," said one ad in Iowa, featuring a Davenport resident identified as Maria. Protect Our Care, a left-leaning healthcare advocacy organisation, said it planned to spend up to US$10 million on ads in the first half of next year, largely focused on urging Republican lawmakers to restore funding to Medicaid. Climate Power and the League of Conservation Voters spent US$500,000 on an ad pressuring lawmakers in six congressional districts to vote against the bill, claiming that it would increase electricity rates, according to its president, Pete Maysmith.
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Surgical Sutures Market Worth US$6.65 billion by 2030 with 6.5% CAGR
DELRAY BEACH, Fla., Aug. 1, 2025 /PRNewswire/ — The global Surgical Sutures Market, valued at US$4.56 billion in 2024 stood at US$4.84 billion in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2025 to 2030, culminating in a forecasted valuation of US$6.65 billion by the end of the period. The demand for surgical sutures is on the rise, driven largely by the increasing frequency of surgical interventions worldwide. This trend is significantly influenced by the aging population, which is more susceptible to chronic conditions such as cardiovascular diseases, diabetes, and orthopedic disorders that often require surgical intervention. Additionally, the rising incidence of trauma and accidental injuries globally contributes to the heightened need for sutures. Advancements in suture technology, including the development of absorbable, antibacterial, and barbed sutures, are crucial in enhancing patient recovery, minimizing post-operative complications, and reducing infection rates. These innovations not only improve surgical outcomes but also contribute to the overall growth of the sutures market by addressing specific clinical needs and improving the efficiency of surgical procedures. Download PDF Brochure: Browse in-depth TOC on 'Surgical Sutures Market'348 – Tables52 – Figures319 – Pages By product, Suture thread dominates the surgical sutures market due to its essential role in wound closure across various surgical procedures. As the core component of any suturing system, it is integral to traditional open surgeries and minimally invasive techniques. The preeminence of suture thread can be attributed to its remarkable versatility, diverse material options, and continuous advancements in design and functionality. Innovations such as non-absorbable, absorbable, antibacterial-coated, and barbed suture threads have expanded their application spectrum across various surgical disciplines, including cardiovascular, orthopedic, gynecologic, and general surgery. Clinicians increasingly opt for threads characterized by high tensile strength, minimal tissue reactivity, and reliable absorption profiles—attributes that leading manufacturers consistently refine to meet the evolving demands of surgical practice. By type, Multifilament sutures dominate the surgical sutures market due to their superior handling properties, reliable knot security, and broad application across various surgical specialties. These sutures are constructed from multiple braided or twisted filaments, which give them enhanced flexibility and tensile strength compared to their monofilament counterparts. This makes multifilament sutures particularly well-suited for surgical procedures that demand precise tissue closure, as they can adapt more readily to the contours of the tissue being sutured. The intricate design of multifilament sutures allows for better manipulation during surgical procedures, enabling surgeons to achieve a secure and stable closure. The improved knot-holding capability of these sutures is crucial in maintaining the integrity of the surgical site, reducing the risk of complications that can arise from loosening or failure. In high-pressure clinical environments, where time is often of the essence, the ease of handling that multifilament sutures provide can streamline surgical processes, ultimately contributing to shorter operation times and improved patient outcomes. Their versatility and effectiveness have made multifilament sutures a preferred choice among surgeons in numerous fields, including general surgery, orthopedics, and plastic surgery. By geography, the surgical sutures market is characterized by five key regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. North America stands at the forefront of this market, bolstered by its advanced healthcare infrastructure, high surgical throughput, and the presence of leading industry players. The region features a robust network of hospitals, ambulatory surgical centers, and specialty clinics that engage in a wide array of complex surgical procedures—including cardiovascular, orthopedic, and general surgeries—all of which rely heavily on high-performance surgical sutures. Particularly, the US accounts for the largest market share due to its aging demographic, the prevalence of lifestyle-related chronic diseases, and an increasing demand for cosmetic and minimally invasive surgical interventions. Furthermore, North America is a hub for technological innovation, housing major corporations such as Ethicon and Medtronic, which consistently introduce cutting-edge suture materials and methodologies. This includes advancements in antimicrobial and absorbable sutures, which are crucial in improving surgical outcomes and patient safety. Request Sample Pages: The key players in the global surgical sutures market are Ethicon [Johnson & Johnson Services, Inc.] (US), Medtronic (Ireland), B. Braun SE (Germany), Advanced Medical Solutions Group Plc (UK), Healthium MedTech Limited (India), Boston Scientific Corporation (US) Zimmer Biomet Holdings, Inc. (US), Stryker (US), Smith+Nephew (UK), Conmed Corporation (US), Internacional Farmacéutica S.A. de C.V. (Mexico), Corza Medical (US), DemeTECH Corporation (US), Unisur Lifecare Pvt. Ltd (India), Assut Europe (Italy), RESORBA Medical GmbH (Germany), KATSAN Katgüt Sanayi ve Tic. A.S. (Turkey), Sutumed Corp. (US), Mellon Medical (Netherlands), Futura Surgicare Pvt. Ltd. (India), GMD Group (Turkey), Lotus Surgicals Pvt Ltd (India), BioSintex (Romania), Meril Life Sciences Pvt. Ltd. (India), and Aqmen Medtech (India). Johnson & Johnson Services, Inc. [Ethicon] (US): Ethicon, a subsidiary of Johnson & Johnson, is at the forefront of the surgical suture industry and is recognized for its advanced, high-quality products and comprehensive surgical solutions. The company excels in critical areas such as manufacturing infrastructure, extensive research and development capabilities, and a nuanced understanding of surgical requirements, enabling it to create cutting-edge wound closure innovations. Ethicon's suture portfolio is versatile, catering to various surgical disciplines, including orthopedic, gynecological, cardiovascular, and general surgery. This range encompasses absorbable and non-absorbable sutures, barbed sutures, antibacterial-coated options, and specialty sutures designed for specific applications. The company has made significant investments in technological innovation, especially in automated suture production and the development of bioengineered materials to promote optimal healing outcomes. Furthermore, Ethicon places a strong emphasis on surgeon education, offering global training programs aimed at enhancing surgical techniques and improving patient outcomes. Medtronic (Ireland) Medtronic stands as a prominent force in the surgical sutures sector, leveraging its extensive expertise in surgical solutions and wound closure technologies. The company's competencies are rooted in its innovative approach to clinical effectiveness, producing a diverse portfolio of sutures that effectively support both conventional and advanced surgical techniques. Renowned for high-performance offerings, Medtronic's sutures emphasize durability, biocompatibility, and ease of handling to cater to various subspecialties, including cardiovascular, gastrointestinal, and general surgery. The company maintains a robust commitment to research and development, focusing on enhancing product performance across a range of sutures, including absorbable, non-absorbable, and barbed varieties designed to meet the dynamic demands of surgical practice. One of Medtronic's significant advantages is its expansive global distribution network, coupled with strong engagement with surgeons, facilitating comprehensive training, education, and clinical support on a worldwide scale. Furthermore, the company strategically utilizes its diverse surgical portfolio to create integrated solutions, often bundling sutures with surgical staplers, energy devices, and ancillary instruments. This approach not only provides value-added offerings to healthcare facilities but also enhances surgical efficiency. With a strategic emphasis on expanding market access in emerging economies and addressing the increasing demand for minimally invasive surgical procedures, Medtronic remains a key and adaptive player within the surgical sutures arena. For more information, Inquire Now! Related Reports: Wound Dressings Market Advanced Wound Care Market Minimally Invasive Surgical Instruments Market Endoscopy Equipment Market Electrosurgery Market Get access to the latest updates on Surgical Sutures Companies and Surgical Sutures Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content:
New Straits Times
6 hours ago
- New Straits Times
US tariff by the numbers
FOLLOWING the US' new tariffs, as posted on the White House website, here's some key data that we have observed: * Mexico faces a 25 per cent fentanyl tariff, 25 per cent cars tariff and 50 per cent tariff on steel, aluminium and copper - all which kick in 90 days. * Goods from the European Union face a range of zero per cent to around 15 per cent tariffs. These rates kick in on Aug 7. * Traditional partners and many smaller or deficit running economies remain at the 10 per cent baseline, often subject to diplomatic negotiation for reductions. * The highest tariffs (49-50 per cent) target small economies with historical trade barriers or oversized trade surpluses to the US (e.g. Lesotho, Cambodia). * Major Asian exporters like Vietnam, India, Taiwan, Indonesia and Malaysia face medium high tariffs (19-25 per cent). * Some countries (e.g. Israel, Iceland) negotiated lower-than-initial rates around 15-17 per cent. We've also summarised it: 10 per cent - Brazil, Falkland Islands, United Kingdom and all other countries not listed in the executive order (including Singapore) 15 per cent - Afghanistan, Angola, Bolivia, Botswana, Cameroon, Chad, Costa Rica, Côte d`Ivoire, Democratic Republic of the Congo, Ecuador, Equatorial Guinea, Fiji, Ghana, Guyana, Iceland, Israel, Japan, Jordan, Lesotho, Liechtenstein, Madagascar, Malawi, Mauritius, Mozambique, Namibia, Nauru, New Zealand, Nigeria, North Macedonia, Norway, Papua New Guinea, South Korea, Trinidad and Tobago, Turkey, Uganda, Vanuatu, Venezuela, Zambia, Zimbabwe 18 per cent - Nicaragua 19 per cent - Cambodia, Indonesia, Malaysia, Pakistan, the Philippines 20 per cent - Bangladesh, Sri Lanka, Thailand, Taiwan, Vietnam 25 per cent - Brunei, India, Kazakhstan, Moldova, Tunisia 30 per cent - Algeria, Bosnia and Herzegovina, Libya, South Africa 35 per cent - Iraq, Serbia, Canada 39 per cent - Switzerland 40 per cent - Laos, Myanmar
